SIETES :: 93091 citas

Resultados de la búsqueda por VARIABILIDAD INTERINDIVIDUAL REFINAR BÚSQUEDA

1.

Montastruc J-L. A propos du Levothyrox® : les réflexions du pharmacologue médical. BIP31.fr 2017;24:60. [Ref.ID 102182]

2.

Passman R. Time in therapeutic range in warfarin-treated patients: is very good good enough?. JAMA 2016;316:872-3. [Ref.ID 100590]

3.

Chekroud AM, Krystal JH. Personalised pharmacotherapy: an interim solution for antidepressant treatment?. BMJ 2015;350:h2502. [Ref.ID 99115]

4.

5.

Steinberg BA. Refined bleeding estimates in adults starting anticoagulants. BMJ 2014;349:g4800. [Ref.ID 98176]

6.

Torjesen I. Personalised medicine trial in lung cancer heralds new partnership. BMJ 2014;348:g2837. [Ref.ID 97965]

7.

Anónimo. Emergency contraceptive pills to carry warnings for reduced effectiveness in women over a certain body weight. Health Canada 2014:26 de marzo. [Ref.ID 97324]

8.

Wright DFB, Al-Sallami HS, Duffull SB. Is the dose of dabigatran really more predictable than warfarin?. Br J Clin Pharmacol 2013;76:997-8. [Ref.ID 96634]

9.

van den Bemt BJF, den Broeder AA, Wolbink G-J, van den Maas A, Hekster YA, van Riel PLCM, Benraad HB, van den hoogen FHJ. The combined use of disease activity and infliximab serum trough concentrations for early prediction of (non-)response to infliximab in rheumatoid arthritis. Br J Clin Pharmacol 2013;76:939-45. [Ref.ID 96632]

10.

Hermann HC. Who will do well on warfarin? Does it matter?. Journal Watch Cardiology Alert 2013:19 de junio. [Ref.ID 95636]

11.

Rane A, Ekström L. Androgens and doping tests: genetic variation and pit-falls. Br J Clin Pharmacol 2012;74:3-15. [Ref.ID 93372]

12.

Ritter JM. Sex, steroids and anabolic androgens in athletics. Br J Clin Pharmacol 2012;74:1-2. [Ref.ID 93371]

13.

14.

Anónimo. Saquinavir: update on potential risk of arrhythmia - reduced dose for initial treatment. Drug Safety Update 2010;4:diciembre. [Ref.ID 89524]

15.

Anónimo. Canadian doctors advise phasing out codeine. BMJ 2010;341:798. [Ref.ID 89510]

16.

Mega JL, Simon T, Collet J-P, Anderson JL, Antman EM, Bliden K, Cannon CP, Danchin N, Giusti B, Gurbel P, Horne BD, Hulot JS, Kastrati A, Montalescot G, Neumann F-J, Shen L, Sibbing D, Steg PG, Trenk D, Wiviott SD, Sabatine MS. Reduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI. A meta-analysis. JAMA 2010;304:1821-30. [Ref.ID 89227]

17.

Fuster V, Sweeny JM. Clopidogrel and the reduced-function CYP2C19 genetic variant. JAMA 2010;304:1839-8140. [Ref.ID 89226]

18.

Rothwell PM. ß blockers in hypertension. Author's reply. Lancet 2010;376:415-6. [Ref.ID 89073]

19.

Cruickshank JM. ß blockers in hypertension. Lancet 2010;376:415. [Ref.ID 89072]

20.

Westhoff CL, Torgal AH, Mayeda ER, Pike MC, Stanczyk FZ. Pharmacokinetics of a combined oral contraceptive in obese and normal-weight women. Contraception 2010;81:474-80. [Ref.ID 88593]